plasmids. 7 To determine the impact of mcr-5, further information on the stability of the mcr-5-harbouring plasmids, their transmission routes and distribution in livestock, food products and humans is needed. These data are necessary to develop efficient risk management strategies to control the spread of mobile phosphoethanolamine transferase conferring reduced susceptibility to colistin in Enterobacteriaceae.
Poor palatability of the new ritonavir formulation is a major obstacle to adherence to treatment in young children Sir, Achieving and maintaining good long-term adherence to treatment and viral suppression remains challenging in children perinatally infected with HIV. Overall virological failure (VF) rates in this group are more than double those in adults, even in high-resource countries. 1 Suboptimal virological suppression may lead to the emergence of drug-resistant viruses, the consequences of which are particularly significant for children who will need antiretrovirals for decades. 2 Only a very limited number of antiretroviral drugs are available for use in young children, in both Northern and Southern countries. Moreover, the poor palatability of some antiretroviral oral solutions (OSs) (especially lopinavir/ritonavir and ritonavir OSs) are a major obstacle to adherence. Thus, there is an urgent need to develop highly active and palatable drugs appropriate for use in young children. In 2016, the ritonavir paediatric formulation used in France was changed: OS was replaced by powder for oral suspension (POS).
We herein describe our experience with the use of this new ritonavir formulation in HIV-1-infected antiretroviral-experienced and virologically suppressed young children. All decisions to switch to ritonavir POS were validated by the local HIV expert teams. Parents/guardians provided informed consent for the anonymous use of their clinical and biological data for biomedical research at the time of data collection.
Between November 2016 and July 2017, antiretroviral regimens containing ritonavir POS were introduced in 10 consecutive virologically suppressed children (see Table 1 ). All of the children had HIV-1 viral loads (VLs) of ,400 copies/mL for at least 12 months. Nine children had VLs of ,50 copies/mL and 7/10 did not experience VF following antiretroviral initiation. In all of the newly introduced antiretroviral regimens, ritonavir POS was coadministered with darunavir OS. The new combinations were introduced in six children as a simplification strategy in order to decrease the amount of OS taken daily and/or to switch to a oncedaily dosing frequency. The four remaining children had previously received a darunavir/ritonavir-based combination, and ritonavir POS was introduced because ritonavir OS was no longer available. Parents were informed about the method of administration for ritonavir POS, as recommended by FDA and EMA guidelines: ritonavir POS should be mixed with soft food, such as apple sauce or vanilla pudding, or mixed with liquid, such as water, chocolate milk or infant formula. Furthermore, its bitter aftertaste may be lessened if peanut butter, hazelnut chocolate spread or blackcurrant syrup are taken immediately after dose administration.
The parents of five children (patients #2, #6, #7, #8, #9) called the paediatricians before the next planned hospital visit to inform them that their children refused to continue ritonavir POS because of its poor palatability. In all cases, a new antiretroviral combination was immediately introduced and children remained virologically suppressed at the time of the next follow-up visit. The parents of the five other children also reported the poor palatability of ritonavir POS. At the first follow-up visit after the switch to ritonavir POS, blood tests revealed VF in one child (patient #10), who was previously virologically suppressed under darunavir/ritonavir OS monotherapy; viraemia rebounded to 4.4 log 10 copies/mL 4 months after the switch to darunavir/ritonavir POS monotherapy. The four remaining children remained virologically suppressed, but two of them (patients #1 and #5) asked the paediatricians to stop ritonavir POS 4.5 and 6 months after its introduction, respectively, because the formulation was no longer acceptable. Overall, at the time of their last visit, only 3/10 children were still receiving ritonavir POS-based combinations, including the child whose viral rebound was recently diagnosed.
Darunavir/ritonavir-and atazanavir/ritonavir-based combinations are now included among preferred antiretroviral regimens in HIV-infected children aged 3 years because of: (i) the availability of paediatric formulations of these drugs; (ii) the high risk of VF in this population for whom drugs with a high genetic barrier to resistance may be preferred; and (iii) the poor palatability and the poor clinical tolerance of lopinavir/ritonavir OS. 3, 4 However, our data suggest that a high proportion of children could refuse the new paediatric formulation of ritonavir because of its poor palatability. Moreover, the acceptability of ritonavir POS seemed worse than that of lopinavir/ritonavir OS and ritonavir OS, for which palatability was already known to be poor. Indeed, 5/7 patients who stopped ritonavir POS were previously virologically suppressed while taking lopinavir/ritonavir OS-or ritonavir OS-based combinations. As ritonavir tablets are often too large to be swallowed by young children, the poor palatability of the ritonavir POS formulation could be a major obstacle to the use of a darunavir-or atazanavir-based regimen in this population. To conclude, paediatricians, children and their families should be informed about the high risk of low adherence to a ritonavir POS-based regimen because of its poor palatability. When treatment with ritonavir POS is initiated, close clinical and virological monitoring of children is needed, even in previously virologically suppressed children, in order to promptly switch to other combinations and prevent emergence of new resistance mutations in the event of VF.
